Skip to content

Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients.

Aug 2026 · New England Journal of Medicine · 0 citations · 11 references
Medicine

TL;DR

Among patients at high risk for ischemic events 12 months after drug-eluting stent implantation, clopidogrel monotherapy was noninferior to extended DAPT with respect to net adverse clinical events at 24 months.

Abstract

Background

The effect of clopidogrel monotherapy as compared with extended dual antiplatelet therapy (DAPT) with clopidogrel and aspirin beyond 12 months after implantation of a drug-eluting stent remains uncertain in patients at high risk for recurrent ischemic events.

Methods

In this open-label noninferiority trial conducted in South Korea, we enrolled patients with high-risk clinical or lesion characteristics in whom a drug-eluting stent had been implanted 12 months earlier and randomly assigned them, in a 1:1 ratio, to receive clopidogrel monotherapy or extended DAPT (clopidogrel plus aspirin). The primary end point was net adverse clinical events, a composite of death from any cause, myocardial infarction, stent thrombosis, stroke, or Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding at 24 months (noninferiority margin, 2.3 percentage points). Key secondary ischemic and bleeding end points were tested in a prespecified hierarchical order.

Results

Of the 3203 patients who underwent randomization, 1601 were assigned to receive clopidogrel monotherapy and 1602 to receive extended DAPT. Over the course of 24 months, a primary end-point event occurred in 80 patients (5.0%) in the monotherapy group and in 81 (5.1%) in the DAPT group (risk difference, -0.1 percentage points; 90% confidence interval [CI], -1.3 to 1.2; P = 0.001 for noninferiority). Death from any cause, myocardial infarction, stent thrombosis, or stroke (the key secondary ischemic end point) occurred in 60 patients (3.7%) in the monotherapy group and in 26 (1.6%) in the DAPT group (hazard ratio, 2.33; 95% CI, 1.47 to 3.69; P<0.001). BARC type 2, 3, or 5 bleeding (the key secondary bleeding end point) occurred in 28 patients (1.8%) in the monotherapy group and in 65 (4.1%) in the DAPT group (hazard ratio, 0.43; 95% CI, 0.27 to 0.67; P<0.001). The incidence of serious adverse events was similar in the two groups.

Conclusions

Among patients at high risk for ischemic events 12 months after drug-eluting stent implantation, clopidogrel monotherapy was noninferior to extended DAPT with respect to net adverse clinical events at 24 months. (Funded by Chong Kun Dang and Samjin; A-CLOSE ClinicalTrials.gov number, NCT03947229.).

View source

Similar papers

Open access Aug 2026

Clopidogrel Versus Dual-Antiplatelet Therapy for Long-Term Maintenance After Coronary Stenting in Ischemic and Bleeding Birisk Patients With Acute Coronary Syndromes and Diabetes: A Prespecified Subgroup Analysis of the OPT-BIRISK Trial.

In birisk patients with acute coronary syndrome who were stable on dual-antiplatelet therapy with clopidogrel plus aspirin for 9 to 12 months after percutaneous coronary intervention, clopidogrel monotherapy for an additional 9 months reduced clinically relevant bleeding without increasing ischemic events compared with...

Dali Zhang, Yi Li, Miao-Han Qiu et al. · 0 citations
Sep 2026

Low-dose ticagrelor combined with aspirin for preventing early neurological deterioration in patients with high-risk non-disabling ischemic cerebrovascular events: a multicenter, prospective, randomized, open-label, clinical trial

Among patients with HR‑NICE within 24 h of onset, low‑dose ticagrelor plus aspirin significantly decreased the incidence of END within 7 days and improved neurological functional outcomes at 90 days compared with clopidogrel plus aspirin, without increasing the risk of bleeding.

Jia-Hui Liu, Hua Cao, Ming-Li Wang et al. · 0 citations
Oct 2026

Low-dose prasugrel versus clopidogrel for dual antiplatelet therapy after percutaneous coronary intervention: insights from the STOPDAPT-2 total cohort.

No significant differences were detected in short-term cardiovascular or bleeding outcomes between low-dose prasugrel-based and clopidogrel-based DAPT in patients after PCI without major in-hospital complications.

T. Isawa, Hirotoshi Watanabe, Takeshi Morimoto et al. · 0 citations
Open access Aug 2026

Early discontinuation of dual antiplatelet therapy after PCI in patients at high bleeding risk: an OCT-guided clinical case

The application of OCT for the evaluation of stent strut endothelialization provides a robust rationale for shortening DAPT duration to 1 month in patients with high hemorrhagic risk, even in the presence of concomitant diabetes mellitus and multiple comorbidities.

A. Prokhorikhin, Yu. V. Kukushkina, D. D. Zubarev et al. · 0 citations
Open access Sep 2026

Clopidogrel monotherapy versus aspirin monotherapy in females and males after percutaneous coronary intervention: a sex-stratified analysis of the SMART-CHOICE 3 trial.

In patients with remote PCI and a high risk of recurrent ischaemic events, clopidogrel monotherapy showed a directionally consistent reduction in the composite endpoint of all-cause death, myocardial infarction, or stroke compared with aspirin in both females and males, supporting the consistency of the treatment effec...

Woo-Duk Kwon, Ki H. Choi, Yonghwan Park et al. · 0 citations
Aug 2026

Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI.

BACKGROUND The safety of omitting up-front treatment with aspirin during primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) remains unclear. METHODS We conducted a multicenter, open-label, randomized trial in Japan involving patients with STEMI who wer...

Kuniaki Takahashi, Ken Kozuma, Yoshihiro Morino et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.